Director – Market Insights & Forecasting
Incyte
Director – Market Insights & Forecasting
Incyte
Biopharmaceutical company pursuing drug discovery.
A global biopharmaceutical company on a mission to Solve On, Incyte follows science to find solutions for patients with unmet medical needs. Through the discovery, development, and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Hematology, Oncology and Inflammation and Autoimmunity
Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe, and Asia.
The Director, Market Insights & Analytics, U.S. Portfolio & Launch Readiness supports U.S. market insights, forecast transition, strategic planning, and launch-readiness analytics for assets approaching commercialization. The role serves as the U.S. commercial bridge between global early-stage forecasting and U.S. launch planning, ensuring assets within approximately two years of expected U.S. launch have clear, pressure-tested assumptions, planning timelines, market context, analytics requirements, and source-of-truth outputs.
This role partners closely with Global Forecasting, U.S. Commercial, Market Insights & Forecasting, Commercial Analytics, Reporting & Decision Support, Finance, Market Access, Medical, Data/Technology, BIS, and other cross-functional stakeholders to translate global forecast inputs into U.S.-specific commercial assumptions, strategic planning materials, launch-readiness reporting requirements, and executive-ready decision support.
The Director reports into Market Insights & Forecasting and has dotted-line accountability to Analytics & Decision Support for dashboard requirements, reporting automation, data structure, and analytical production standards. The role ensures near-launch assets are incorporated into U.S. strategic planning, forecast governance, executive reporting, and future-state commercial intelligence capabilities without duplicating early-stage global forecasting ownership.
This is an individual contributor role that leads through influence across global and U.S. stakeholders, with no direct people-management responsibility.
Key Responsibilities
People Leadership Scope
Qualifications and Education
Incyte develops and sells medicines by discovering and developing new drugs, focusing on diseases in inflammation, autoimmunity, and blood cancers. Its core product, Jakafi (ruxolitinib), is a JAK1/2 inhibitor approved to treat a rare blood cancer and works by blocking JAK enzymes to reduce abnormal blood cell growth. The company also expands its pipeline through research collaborations, partnerships, and acquisitions, such as the 2024 purchase of Escient Pharmaceuticals to strengthen its inflammation and autoimmune portfolio. Unlike some competitors that rely mainly on internal programs, Incyte combines in-house discovery with external collaborations and strategic deals to grow its drug candidates from early research to approved therapies. The goal is to deliver medicines that help patients with serious diseases by building a diverse, clinically validated portfolio of treatments through internal efforts and partnerships.
Explore more opportunities at Incyte